Vinpocetine and Sorafenib: Combination inhibits the PI3K/AKT pathway, reducing Sorafenib-resistant HCC cells by blocking key components such as PI3K, phospho-mTOR, and phospho-AKT. This evidence concerns the gene MTOR and hepatocellular carcinoma.